Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

Nagrial, A. M., Chin, V. T., Sjoquist, K. M., Pajic, M., Horvath, L. G., Biankin, A. and Yip, D. (2015) Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology, 96(3), pp. 483-497. (doi:10.1016/j.critrevonc.2015.07.007) (PMID:26481952)

Full text not currently available from Enlighten.

Abstract

There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Biankin, Professor Andrew
Authors: Nagrial, A. M., Chin, V. T., Sjoquist, K. M., Pajic, M., Horvath, L. G., Biankin, A., and Yip, D.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Critical Reviews in Oncology/Hematology
Publisher:Elsevier
ISSN:1040-8428
ISSN (Online):1879-0461

University Staff: Request a correction | Enlighten Editors: Update this record